# Merck builds new TICE BCG manufacturing facility to triple capacity

Merck is building a new manufacturing facility for TICE BCG, investing more than $650 million. The facility aims to triple manufacturing capacity, but opening has been delayed beyond the original end-of-2026 target due to mechanical interdependencies.

- Type: New facility
- Announced: 2025-05-30
- Where: United States
- Value: $650.0M
- Status: under construction
- Capacity: triple TICE BCG manufacturing capacity
- Products: TICE BCG (BCG LIVE for intravesical use)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Merck](https://endata.com/companies/1841.md)

## Sources

- [merck.com](https://www.merck.com/stories/addressing-the-global-shortage-of-tice-bcg/), 2025-05-30: "This investment reaffirms Merck’s longstanding commitment to producing this medicine, and all our medicines, for patients who need them."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.